INDOBUFEN AND PENTOXIFYLLINE IN TREATMENT OF PATIENTS WITH ATHEROSCLEROSIS OF LOWER-EXTREMITIES - CLINICAL AND HEMOSTASIOLOGICAL EFFECTS

Clinical and hemostasiological effects of indobufen and pentoxifylline were compared in 71 patients with atherosclerosis of lower extremitie s verified by doppler ultrasound or angiography, All patients had stab le stage II intermittent claudication. Indobufen (400 mg/day) was give n to 35 patients and pentoxifylline (600 mg/day) - to 36 patients. Dur ation of the study was 6 mounths. Treatment was stopped prematurely in 13 patients because of exacerbation of ulcer in 2/0, diagnosis of can cer in 1/1, dyskinesia of bile passages in 0/2, posttraumatic enucleat ion in 1/0, stroke in 0/2 patients in indobufen and pentoxifylline gro ups, respectively. Both drugs significantly increased walking distance but by the end of 6 months efficacy of indobufen was considerably hig her. Results of treatment were related to levels of cholesterol and d- dimer, Indobufen diminished sensitivity of platelets to main inducers of aggregation while pentoxifylline blocked initial steps of coagulati on (at the stage of prothrombin activation) and reduced concent of pla sminogen activator inhibitor.